To our surprise, the CD47 blockade did not recapitulate the compelling anti-tumor efficacy of RT conferred by Sirpα−/− BMDM infusion, despite both modalities disrupting the CD47-SIRPα axis. The gene discussed is CD47; the disease is neoplasm.